nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—AGTR1—pancreatic cancer	0.488	1	CbGaD
Irbesartan—CYP2C8—Tamoxifen—pancreatic cancer	0.0255	0.101	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—pancreatic cancer	0.0248	0.0982	CbGbCtD
Irbesartan—CYP2C8—Erlotinib—pancreatic cancer	0.0217	0.0858	CbGbCtD
Irbesartan—CYP1A2—Tamoxifen—pancreatic cancer	0.0197	0.0781	CbGbCtD
Irbesartan—CYP2C8—Fluorouracil—pancreatic cancer	0.0188	0.0744	CbGbCtD
Irbesartan—CYP2C9—Tamoxifen—pancreatic cancer	0.0178	0.0704	CbGbCtD
Irbesartan—CYP1A2—Erlotinib—pancreatic cancer	0.0168	0.0664	CbGbCtD
Irbesartan—CYP2D6—Tamoxifen—pancreatic cancer	0.0163	0.0644	CbGbCtD
Irbesartan—CYP1A2—Fluorouracil—pancreatic cancer	0.0145	0.0576	CbGbCtD
Irbesartan—CYP2D6—Erlotinib—pancreatic cancer	0.0138	0.0547	CbGbCtD
Irbesartan—CYP2C9—Fluorouracil—pancreatic cancer	0.0131	0.0519	CbGbCtD
Irbesartan—CYP3A4—Tamoxifen—pancreatic cancer	0.0103	0.0409	CbGbCtD
Irbesartan—CYP3A4—Erlotinib—pancreatic cancer	0.00879	0.0348	CbGbCtD
Irbesartan—CYP3A4—Irinotecan—pancreatic cancer	0.00794	0.0314	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—pancreatic cancer	0.00682	0.027	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—pancreatic cancer	0.00582	0.023	CbGbCtD
Irbesartan—CYP3A4—Sunitinib—pancreatic cancer	0.00579	0.0229	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—pancreatic cancer	0.00434	0.0172	CbGbCtD
Irbesartan—Forasartan—AGTR1—pancreatic cancer	0.00178	0.303	CrCbGaD
Irbesartan—Tasosartan—AGTR1—pancreatic cancer	0.00108	0.184	CrCbGaD
Irbesartan—Valsartan—AGTR1—pancreatic cancer	0.000937	0.159	CrCbGaD
Irbesartan—Olmesartan—AGTR1—pancreatic cancer	0.000913	0.155	CrCbGaD
Irbesartan—Candesartan—AGTR1—pancreatic cancer	0.00071	0.121	CrCbGaD
Irbesartan—Losartan—AGTR1—pancreatic cancer	0.000457	0.0778	CrCbGaD
Irbesartan—Pancreatitis—Doxorubicin—pancreatic cancer	8.85e-05	0.000641	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—pancreatic cancer	8.81e-05	0.000637	CcSEcCtD
Irbesartan—Cough—Docetaxel—pancreatic cancer	8.8e-05	0.000637	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—pancreatic cancer	8.8e-05	0.000637	CcSEcCtD
Irbesartan—Hypersensitivity—Irinotecan—pancreatic cancer	8.77e-05	0.000635	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—pancreatic cancer	8.75e-05	0.000634	CcSEcCtD
Irbesartan—Hypertension—Docetaxel—pancreatic cancer	8.71e-05	0.00063	CcSEcCtD
Irbesartan—Chest pain—Docetaxel—pancreatic cancer	8.58e-05	0.000622	CcSEcCtD
Irbesartan—Arthralgia—Docetaxel—pancreatic cancer	8.58e-05	0.000622	CcSEcCtD
Irbesartan—Myalgia—Docetaxel—pancreatic cancer	8.58e-05	0.000622	CcSEcCtD
Irbesartan—Nausea—Sunitinib—pancreatic cancer	8.58e-05	0.000621	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—pancreatic cancer	8.56e-05	0.000619	CcSEcCtD
Irbesartan—Asthenia—Irinotecan—pancreatic cancer	8.54e-05	0.000618	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	8.53e-05	0.000617	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—pancreatic cancer	8.48e-05	0.000614	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—pancreatic cancer	8.46e-05	0.000612	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—pancreatic cancer	8.46e-05	0.000612	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—pancreatic cancer	8.45e-05	0.000611	CcSEcCtD
Irbesartan—Hypersensitivity—Fluorouracil—pancreatic cancer	8.4e-05	0.000608	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—pancreatic cancer	8.4e-05	0.000608	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	8.39e-05	0.000608	CcSEcCtD
Irbesartan—Asthenia—Gemcitabine—pancreatic cancer	8.32e-05	0.000602	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.24e-05	0.000597	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—pancreatic cancer	8.23e-05	0.000596	CcSEcCtD
Irbesartan—Oedema—Docetaxel—pancreatic cancer	8.23e-05	0.000596	CcSEcCtD
Irbesartan—Anaphylactic shock—Docetaxel—pancreatic cancer	8.23e-05	0.000596	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—pancreatic cancer	8.22e-05	0.000595	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—pancreatic cancer	8.21e-05	0.000594	CcSEcCtD
Irbesartan—Pruritus—Gemcitabine—pancreatic cancer	8.2e-05	0.000594	CcSEcCtD
Irbesartan—Infection—Docetaxel—pancreatic cancer	8.18e-05	0.000592	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—pancreatic cancer	8.15e-05	0.00059	CcSEcCtD
Irbesartan—Diarrhoea—Irinotecan—pancreatic cancer	8.15e-05	0.00059	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—pancreatic cancer	8.12e-05	0.000588	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—pancreatic cancer	8.1e-05	0.000586	CcSEcCtD
Irbesartan—Shock—Docetaxel—pancreatic cancer	8.1e-05	0.000586	CcSEcCtD
Irbesartan—Nervous system disorder—Docetaxel—pancreatic cancer	8.07e-05	0.000584	CcSEcCtD
Irbesartan—Pruritus—Fluorouracil—pancreatic cancer	8.07e-05	0.000584	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—pancreatic cancer	8.06e-05	0.000583	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—pancreatic cancer	8.03e-05	0.000581	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—pancreatic cancer	7.99e-05	0.000579	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—pancreatic cancer	7.95e-05	0.000576	CcSEcCtD
Irbesartan—Diarrhoea—Gemcitabine—pancreatic cancer	7.93e-05	0.000574	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—pancreatic cancer	7.92e-05	0.000573	CcSEcCtD
Irbesartan—Dizziness—Irinotecan—pancreatic cancer	7.87e-05	0.00057	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—pancreatic cancer	7.85e-05	0.000568	CcSEcCtD
Irbesartan—Anorexia—Docetaxel—pancreatic cancer	7.84e-05	0.000568	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—pancreatic cancer	7.83e-05	0.000567	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—pancreatic cancer	7.83e-05	0.000567	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—pancreatic cancer	7.83e-05	0.000567	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—pancreatic cancer	7.81e-05	0.000566	CcSEcCtD
Irbesartan—Diarrhoea—Fluorouracil—pancreatic cancer	7.8e-05	0.000565	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—pancreatic cancer	7.77e-05	0.000563	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—pancreatic cancer	7.75e-05	0.000561	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—pancreatic cancer	7.72e-05	0.000559	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—pancreatic cancer	7.7e-05	0.000557	CcSEcCtD
Irbesartan—Hypotension—Docetaxel—pancreatic cancer	7.69e-05	0.000557	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—pancreatic cancer	7.68e-05	0.000556	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—pancreatic cancer	7.66e-05	0.000554	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—pancreatic cancer	7.62e-05	0.000551	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—pancreatic cancer	7.6e-05	0.00055	CcSEcCtD
Irbesartan—Vomiting—Irinotecan—pancreatic cancer	7.57e-05	0.000548	CcSEcCtD
Irbesartan—Dizziness—Fluorouracil—pancreatic cancer	7.54e-05	0.000546	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—pancreatic cancer	7.53e-05	0.000545	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—pancreatic cancer	7.52e-05	0.000544	CcSEcCtD
Irbesartan—Rash—Irinotecan—pancreatic cancer	7.51e-05	0.000543	CcSEcCtD
Irbesartan—Dermatitis—Irinotecan—pancreatic cancer	7.5e-05	0.000543	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.5e-05	0.000543	CcSEcCtD
Irbesartan—Headache—Irinotecan—pancreatic cancer	7.46e-05	0.00054	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—pancreatic cancer	7.39e-05	0.000535	CcSEcCtD
Irbesartan—Vomiting—Gemcitabine—pancreatic cancer	7.37e-05	0.000534	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—pancreatic cancer	7.36e-05	0.000533	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—pancreatic cancer	7.34e-05	0.000531	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—pancreatic cancer	7.32e-05	0.00053	CcSEcCtD
Irbesartan—Rash—Gemcitabine—pancreatic cancer	7.31e-05	0.000529	CcSEcCtD
Irbesartan—Dermatitis—Gemcitabine—pancreatic cancer	7.31e-05	0.000529	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—pancreatic cancer	7.28e-05	0.000527	CcSEcCtD
Irbesartan—Headache—Gemcitabine—pancreatic cancer	7.26e-05	0.000526	CcSEcCtD
Irbesartan—Flushing—Epirubicin—pancreatic cancer	7.25e-05	0.000525	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—pancreatic cancer	7.25e-05	0.000525	CcSEcCtD
Irbesartan—Vomiting—Fluorouracil—pancreatic cancer	7.25e-05	0.000525	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—pancreatic cancer	7.25e-05	0.000525	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—pancreatic cancer	7.24e-05	0.000524	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—pancreatic cancer	7.23e-05	0.000523	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.19e-05	0.000521	CcSEcCtD
Irbesartan—Rash—Fluorouracil—pancreatic cancer	7.19e-05	0.00052	CcSEcCtD
Irbesartan—Dermatitis—Fluorouracil—pancreatic cancer	7.18e-05	0.00052	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—pancreatic cancer	7.17e-05	0.000519	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—pancreatic cancer	7.15e-05	0.000518	CcSEcCtD
Irbesartan—Headache—Fluorouracil—pancreatic cancer	7.14e-05	0.000517	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—pancreatic cancer	7.14e-05	0.000517	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—pancreatic cancer	7.12e-05	0.000516	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.1e-05	0.000514	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—pancreatic cancer	7.1e-05	0.000514	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—pancreatic cancer	7.1e-05	0.000514	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—pancreatic cancer	7.09e-05	0.000513	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—pancreatic cancer	7.09e-05	0.000513	CcSEcCtD
Irbesartan—Nausea—Irinotecan—pancreatic cancer	7.07e-05	0.000512	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—pancreatic cancer	7.06e-05	0.000511	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—pancreatic cancer	7.04e-05	0.00051	CcSEcCtD
Irbesartan—Constipation—Docetaxel—pancreatic cancer	7.04e-05	0.000509	CcSEcCtD
Irbesartan—Pain—Docetaxel—pancreatic cancer	7.04e-05	0.000509	CcSEcCtD
Irbesartan—Chills—Epirubicin—pancreatic cancer	7.01e-05	0.000508	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—pancreatic cancer	6.98e-05	0.000505	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—pancreatic cancer	6.97e-05	0.000504	CcSEcCtD
Irbesartan—Nausea—Gemcitabine—pancreatic cancer	6.89e-05	0.000499	CcSEcCtD
Irbesartan—Erythema—Epirubicin—pancreatic cancer	6.8e-05	0.000492	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—pancreatic cancer	6.8e-05	0.000492	CcSEcCtD
Irbesartan—Feeling abnormal—Docetaxel—pancreatic cancer	6.78e-05	0.000491	CcSEcCtD
Irbesartan—Nausea—Fluorouracil—pancreatic cancer	6.77e-05	0.00049	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—pancreatic cancer	6.74e-05	0.000488	CcSEcCtD
Irbesartan—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.73e-05	0.000487	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—pancreatic cancer	6.71e-05	0.000486	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—pancreatic cancer	6.71e-05	0.000486	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—pancreatic cancer	6.7e-05	0.000485	CcSEcCtD
Irbesartan—Tension—Epirubicin—pancreatic cancer	6.67e-05	0.000483	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—pancreatic cancer	6.66e-05	0.000482	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—pancreatic cancer	6.61e-05	0.000478	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—pancreatic cancer	6.56e-05	0.000475	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—pancreatic cancer	6.54e-05	0.000473	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—pancreatic cancer	6.53e-05	0.000473	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.52e-05	0.000472	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—pancreatic cancer	6.51e-05	0.000471	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—pancreatic cancer	6.51e-05	0.000471	CcSEcCtD
Irbesartan—Chills—Doxorubicin—pancreatic cancer	6.49e-05	0.00047	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—pancreatic cancer	6.46e-05	0.000468	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—pancreatic cancer	6.41e-05	0.000464	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—pancreatic cancer	6.31e-05	0.000457	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—pancreatic cancer	6.29e-05	0.000456	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—pancreatic cancer	6.29e-05	0.000456	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—pancreatic cancer	6.29e-05	0.000455	CcSEcCtD
Irbesartan—Agitation—Epirubicin—pancreatic cancer	6.25e-05	0.000452	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—pancreatic cancer	6.2e-05	0.000449	CcSEcCtD
Irbesartan—Tension—Doxorubicin—pancreatic cancer	6.18e-05	0.000447	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—pancreatic cancer	6.16e-05	0.000446	CcSEcCtD
Irbesartan—Malaise—Epirubicin—pancreatic cancer	6.13e-05	0.000444	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—pancreatic cancer	6.11e-05	0.000443	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—pancreatic cancer	6.11e-05	0.000442	CcSEcCtD
Irbesartan—Syncope—Epirubicin—pancreatic cancer	6.1e-05	0.000442	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—pancreatic cancer	6.09e-05	0.000441	CcSEcCtD
Irbesartan—Hypersensitivity—Docetaxel—pancreatic cancer	6.06e-05	0.000439	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—pancreatic cancer	6.05e-05	0.000438	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—pancreatic cancer	5.98e-05	0.000433	CcSEcCtD
Irbesartan—Cough—Epirubicin—pancreatic cancer	5.93e-05	0.00043	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—pancreatic cancer	5.93e-05	0.000429	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—pancreatic cancer	5.9e-05	0.000427	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—pancreatic cancer	5.87e-05	0.000425	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.84e-05	0.000423	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—pancreatic cancer	5.82e-05	0.000422	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—pancreatic cancer	5.82e-05	0.000421	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—pancreatic cancer	5.79e-05	0.000419	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—pancreatic cancer	5.79e-05	0.000419	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—pancreatic cancer	5.79e-05	0.000419	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—pancreatic cancer	5.78e-05	0.000419	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—pancreatic cancer	5.77e-05	0.000418	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.75e-05	0.000416	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—pancreatic cancer	5.72e-05	0.000414	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—pancreatic cancer	5.68e-05	0.000411	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—pancreatic cancer	5.66e-05	0.00041	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—pancreatic cancer	5.65e-05	0.000409	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—pancreatic cancer	5.64e-05	0.000409	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—pancreatic cancer	5.63e-05	0.000408	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—pancreatic cancer	5.63e-05	0.000408	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—pancreatic cancer	5.55e-05	0.000402	CcSEcCtD
Irbesartan—Oedema—Epirubicin—pancreatic cancer	5.55e-05	0.000402	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—pancreatic cancer	5.53e-05	0.0004	CcSEcCtD
Irbesartan—Infection—Epirubicin—pancreatic cancer	5.51e-05	0.000399	CcSEcCtD
Irbesartan—Cough—Doxorubicin—pancreatic cancer	5.49e-05	0.000398	CcSEcCtD
Irbesartan—Shock—Epirubicin—pancreatic cancer	5.46e-05	0.000395	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—pancreatic cancer	5.44e-05	0.000394	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—pancreatic cancer	5.44e-05	0.000394	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—pancreatic cancer	5.43e-05	0.000393	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—pancreatic cancer	5.43e-05	0.000393	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—pancreatic cancer	5.42e-05	0.000392	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—pancreatic cancer	5.39e-05	0.00039	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—pancreatic cancer	5.37e-05	0.000388	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—pancreatic cancer	5.36e-05	0.000388	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—pancreatic cancer	5.36e-05	0.000388	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—pancreatic cancer	5.36e-05	0.000388	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—pancreatic cancer	5.34e-05	0.000387	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.32e-05	0.000385	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—pancreatic cancer	5.29e-05	0.000383	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—pancreatic cancer	5.29e-05	0.000383	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—pancreatic cancer	5.24e-05	0.000379	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—pancreatic cancer	5.23e-05	0.000379	CcSEcCtD
Irbesartan—Rash—Docetaxel—pancreatic cancer	5.19e-05	0.000376	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—pancreatic cancer	5.19e-05	0.000376	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—pancreatic cancer	5.18e-05	0.000375	CcSEcCtD
Irbesartan—Headache—Docetaxel—pancreatic cancer	5.16e-05	0.000373	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—pancreatic cancer	5.14e-05	0.000372	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.14e-05	0.000372	CcSEcCtD
Irbesartan—Infection—Doxorubicin—pancreatic cancer	5.1e-05	0.000369	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.06e-05	0.000366	CcSEcCtD
Irbesartan—Shock—Doxorubicin—pancreatic cancer	5.05e-05	0.000366	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—pancreatic cancer	5.04e-05	0.000365	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.03e-05	0.000364	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—pancreatic cancer	5.01e-05	0.000363	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—pancreatic cancer	4.99e-05	0.000361	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—pancreatic cancer	4.98e-05	0.000361	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.97e-05	0.000359	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—pancreatic cancer	4.95e-05	0.000358	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—pancreatic cancer	4.93e-05	0.000357	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—pancreatic cancer	4.9e-05	0.000354	CcSEcCtD
Irbesartan—Nausea—Docetaxel—pancreatic cancer	4.89e-05	0.000354	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—pancreatic cancer	4.89e-05	0.000354	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—pancreatic cancer	4.83e-05	0.000349	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—pancreatic cancer	4.8e-05	0.000347	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.79e-05	0.000347	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—pancreatic cancer	4.79e-05	0.000346	CcSEcCtD
Irbesartan—Pain—Epirubicin—pancreatic cancer	4.75e-05	0.000344	CcSEcCtD
Irbesartan—Constipation—Epirubicin—pancreatic cancer	4.75e-05	0.000344	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.68e-05	0.000339	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—pancreatic cancer	4.61e-05	0.000334	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—pancreatic cancer	4.58e-05	0.000332	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—pancreatic cancer	4.57e-05	0.000331	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—pancreatic cancer	4.57e-05	0.000331	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.54e-05	0.000329	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—pancreatic cancer	4.52e-05	0.000327	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—pancreatic cancer	4.46e-05	0.000323	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.43e-05	0.000321	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—pancreatic cancer	4.43e-05	0.000321	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—pancreatic cancer	4.41e-05	0.000319	CcSEcCtD
Irbesartan—Pain—Doxorubicin—pancreatic cancer	4.39e-05	0.000318	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—pancreatic cancer	4.39e-05	0.000318	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—pancreatic cancer	4.39e-05	0.000318	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—pancreatic cancer	4.39e-05	0.000318	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—pancreatic cancer	4.23e-05	0.000306	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.2e-05	0.000304	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—pancreatic cancer	4.09e-05	0.000296	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—pancreatic cancer	4.08e-05	0.000295	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—pancreatic cancer	4.06e-05	0.000294	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—pancreatic cancer	4.06e-05	0.000294	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—pancreatic cancer	3.98e-05	0.000288	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—pancreatic cancer	3.93e-05	0.000284	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—pancreatic cancer	3.8e-05	0.000275	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—pancreatic cancer	3.78e-05	0.000274	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—pancreatic cancer	3.68e-05	0.000267	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—pancreatic cancer	3.67e-05	0.000266	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—pancreatic cancer	3.63e-05	0.000263	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—pancreatic cancer	3.53e-05	0.000256	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—pancreatic cancer	3.51e-05	0.000254	CcSEcCtD
Irbesartan—Rash—Epirubicin—pancreatic cancer	3.5e-05	0.000253	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—pancreatic cancer	3.5e-05	0.000253	CcSEcCtD
Irbesartan—Headache—Epirubicin—pancreatic cancer	3.48e-05	0.000252	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—pancreatic cancer	3.4e-05	0.000246	CcSEcCtD
Irbesartan—Nausea—Epirubicin—pancreatic cancer	3.3e-05	0.000239	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—pancreatic cancer	3.27e-05	0.000236	CcSEcCtD
Irbesartan—Rash—Doxorubicin—pancreatic cancer	3.24e-05	0.000234	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—pancreatic cancer	3.24e-05	0.000234	CcSEcCtD
Irbesartan—Headache—Doxorubicin—pancreatic cancer	3.22e-05	0.000233	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—pancreatic cancer	3.05e-05	0.000221	CcSEcCtD
Irbesartan—CYP2D6—Metabolism—ARG2—pancreatic cancer	1.22e-05	0.000106	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HIF1A—pancreatic cancer	1.21e-05	0.000105	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSC2—pancreatic cancer	1.21e-05	0.000105	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ARG2—pancreatic cancer	1.21e-05	0.000105	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CD—pancreatic cancer	1.2e-05	0.000104	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.19e-05	0.000103	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.18e-05	0.000103	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APOE—pancreatic cancer	1.18e-05	0.000103	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CG—pancreatic cancer	1.18e-05	0.000103	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—pancreatic cancer	1.17e-05	0.000102	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CD44—pancreatic cancer	1.17e-05	0.000102	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KDR—pancreatic cancer	1.16e-05	0.000101	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.14e-05	9.96e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—pancreatic cancer	1.14e-05	9.92e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—pancreatic cancer	1.14e-05	9.91e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—pancreatic cancer	1.13e-05	9.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.13e-05	9.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GCG—pancreatic cancer	1.12e-05	9.75e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD4—pancreatic cancer	1.11e-05	9.62e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKBIA—pancreatic cancer	1.1e-05	9.58e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOTCH1—pancreatic cancer	1.09e-05	9.49e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CD—pancreatic cancer	1.08e-05	9.42e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HES1—pancreatic cancer	1.08e-05	9.39e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—pancreatic cancer	1.08e-05	9.36e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—pancreatic cancer	1.07e-05	9.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.07e-05	9.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CG—pancreatic cancer	1.07e-05	9.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—pancreatic cancer	1.07e-05	9.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMP—pancreatic cancer	1.06e-05	9.25e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.05e-05	9.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGF—pancreatic cancer	1.05e-05	9.17e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—STK11—pancreatic cancer	1.05e-05	9.16e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GLP1R—pancreatic cancer	1.04e-05	9.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CB—pancreatic cancer	1.04e-05	9.06e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CD—pancreatic cancer	1.04e-05	9.03e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.03e-05	8.97e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DPYD—pancreatic cancer	1.03e-05	8.94e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—pancreatic cancer	1e-05	8.71e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—pancreatic cancer	9.95e-06	8.65e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.89e-06	8.6e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—pancreatic cancer	9.89e-06	8.6e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	9.75e-06	8.48e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—pancreatic cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—pancreatic cancer	9.67e-06	8.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	9.65e-06	8.39e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—pancreatic cancer	9.58e-06	8.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—pancreatic cancer	9.46e-06	8.23e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CB—pancreatic cancer	9.45e-06	8.21e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CD—pancreatic cancer	9.38e-06	8.16e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—pancreatic cancer	9.33e-06	8.11e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	9.31e-06	8.1e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	9.29e-06	8.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—pancreatic cancer	9.24e-06	8.03e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—pancreatic cancer	9.18e-06	7.98e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRSS1—pancreatic cancer	9.18e-06	7.98e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—pancreatic cancer	9.15e-06	7.95e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TYMS—pancreatic cancer	9.07e-06	7.88e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—pancreatic cancer	9.05e-06	7.87e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CB—pancreatic cancer	9.05e-06	7.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HIF1A—pancreatic cancer	9.05e-06	7.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSC2—pancreatic cancer	9.02e-06	7.85e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMP—pancreatic cancer	9.01e-06	7.84e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—pancreatic cancer	9e-06	7.83e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—pancreatic cancer	8.97e-06	7.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APOE—pancreatic cancer	8.83e-06	7.68e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—pancreatic cancer	8.78e-06	7.64e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	8.7e-06	7.57e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—pancreatic cancer	8.65e-06	7.52e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GLP1R—pancreatic cancer	8.58e-06	7.46e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GLP1R—pancreatic cancer	8.5e-06	7.39e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.48e-06	7.38e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DPYD—pancreatic cancer	8.44e-06	7.34e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	8.44e-06	7.34e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—pancreatic cancer	8.37e-06	7.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DPYD—pancreatic cancer	8.36e-06	7.27e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SRC—pancreatic cancer	8.35e-06	7.26e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKBIA—pancreatic cancer	8.23e-06	7.16e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CB—pancreatic cancer	8.17e-06	7.11e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—pancreatic cancer	8.16e-06	7.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH1—pancreatic cancer	8.15e-06	7.09e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—pancreatic cancer	8.13e-06	7.07e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—pancreatic cancer	8.08e-06	7.02e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—pancreatic cancer	8.05e-06	7e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—pancreatic cancer	8.03e-06	6.98e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	8.01e-06	6.96e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—pancreatic cancer	7.97e-06	6.93e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ARG2—pancreatic cancer	7.96e-06	6.92e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	7.94e-06	6.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGF—pancreatic cancer	7.88e-06	6.85e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—pancreatic cancer	7.86e-06	6.83e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.85e-06	6.83e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—pancreatic cancer	7.82e-06	6.8e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—pancreatic cancer	7.8e-06	6.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—pancreatic cancer	7.59e-06	6.6e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.58e-06	6.59e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—SRC—pancreatic cancer	7.57e-06	6.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD44—pancreatic cancer	7.55e-06	6.57e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—pancreatic cancer	7.52e-06	6.54e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—pancreatic cancer	7.48e-06	6.51e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—pancreatic cancer	7.46e-06	6.49e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.44e-06	6.47e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.39e-06	6.43e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOE—pancreatic cancer	7.37e-06	6.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.33e-06	6.37e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—pancreatic cancer	7.32e-06	6.36e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—pancreatic cancer	7.32e-06	6.36e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—pancreatic cancer	7.3e-06	6.35e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—pancreatic cancer	7.28e-06	6.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GLP1R—pancreatic cancer	7.26e-06	6.32e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—pancreatic cancer	7.25e-06	6.3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GCG—pancreatic cancer	7.24e-06	6.3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.15e-06	6.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—pancreatic cancer	7.11e-06	6.18e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—pancreatic cancer	7.06e-06	6.14e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—pancreatic cancer	7.01e-06	6.09e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.98e-06	6.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMP—pancreatic cancer	6.96e-06	6.05e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—pancreatic cancer	6.91e-06	6.01e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.9e-06	6e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—pancreatic cancer	6.89e-06	5.99e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STK11—pancreatic cancer	6.81e-06	5.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	6.78e-06	5.9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.71e-06	5.84e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—pancreatic cancer	6.65e-06	5.79e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—pancreatic cancer	6.63e-06	5.77e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—pancreatic cancer	6.55e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.48e-06	5.63e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—pancreatic cancer	6.42e-06	5.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.39e-06	5.56e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—pancreatic cancer	6.38e-06	5.55e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—pancreatic cancer	6.35e-06	5.52e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—pancreatic cancer	6.32e-06	5.49e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—pancreatic cancer	6.3e-06	5.48e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—pancreatic cancer	6.27e-06	5.45e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD44—pancreatic cancer	6.2e-06	5.39e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD44—pancreatic cancer	6.15e-06	5.35e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—pancreatic cancer	6.14e-06	5.34e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—pancreatic cancer	6.11e-06	5.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.02e-06	5.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.96e-06	5.19e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GCG—pancreatic cancer	5.94e-06	5.17e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.9e-06	5.13e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GCG—pancreatic cancer	5.89e-06	5.12e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—pancreatic cancer	5.88e-06	5.11e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—pancreatic cancer	5.87e-06	5.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—pancreatic cancer	5.87e-06	5.1e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—pancreatic cancer	5.86e-06	5.09e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—pancreatic cancer	5.86e-06	5.09e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—pancreatic cancer	5.85e-06	5.09e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—pancreatic cancer	5.76e-06	5.01e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—pancreatic cancer	5.74e-06	4.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—pancreatic cancer	5.62e-06	4.88e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GLP1R—pancreatic cancer	5.61e-06	4.88e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STK11—pancreatic cancer	5.59e-06	4.86e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STK11—pancreatic cancer	5.54e-06	4.82e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—pancreatic cancer	5.52e-06	4.8e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DPYD—pancreatic cancer	5.52e-06	4.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—pancreatic cancer	5.47e-06	4.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—pancreatic cancer	5.42e-06	4.72e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—pancreatic cancer	5.41e-06	4.71e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—pancreatic cancer	5.33e-06	4.63e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—pancreatic cancer	5.31e-06	4.62e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—pancreatic cancer	5.28e-06	4.59e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD44—pancreatic cancer	5.25e-06	4.57e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	5.23e-06	4.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.2e-06	4.52e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—pancreatic cancer	5.19e-06	4.51e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.14e-06	4.47e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—pancreatic cancer	5.1e-06	4.43e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.1e-06	4.43e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—pancreatic cancer	5.05e-06	4.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GCG—pancreatic cancer	5.04e-06	4.38e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—pancreatic cancer	4.98e-06	4.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—pancreatic cancer	4.89e-06	4.26e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—pancreatic cancer	4.82e-06	4.19e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.81e-06	4.18e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—pancreatic cancer	4.77e-06	4.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—pancreatic cancer	4.77e-06	4.14e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOE—pancreatic cancer	4.76e-06	4.14e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STK11—pancreatic cancer	4.73e-06	4.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—pancreatic cancer	4.72e-06	4.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—pancreatic cancer	4.71e-06	4.09e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—pancreatic cancer	4.7e-06	4.09e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—pancreatic cancer	4.61e-06	4.01e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.51e-06	3.92e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—pancreatic cancer	4.51e-06	3.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.44e-06	3.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—pancreatic cancer	4.41e-06	3.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—pancreatic cancer	4.39e-06	3.81e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—pancreatic cancer	4.37e-06	3.8e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	4.3e-06	3.74e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—pancreatic cancer	4.29e-06	3.73e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—pancreatic cancer	4.15e-06	3.61e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.07e-06	3.54e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—pancreatic cancer	4.07e-06	3.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD44—pancreatic cancer	4.05e-06	3.53e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—pancreatic cancer	4.05e-06	3.52e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOE—pancreatic cancer	3.91e-06	3.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GCG—pancreatic cancer	3.89e-06	3.38e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOE—pancreatic cancer	3.88e-06	3.37e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	3.78e-06	3.29e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—pancreatic cancer	3.72e-06	3.24e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.67e-06	3.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STK11—pancreatic cancer	3.65e-06	3.18e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—pancreatic cancer	3.6e-06	3.13e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.53e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	3.5e-06	3.04e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—pancreatic cancer	3.44e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.41e-06	2.96e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—pancreatic cancer	3.38e-06	2.94e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOE—pancreatic cancer	3.31e-06	2.88e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	3.29e-06	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—pancreatic cancer	3.26e-06	2.84e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.14e-06	2.73e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.14e-06	2.73e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—pancreatic cancer	3.11e-06	2.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.1e-06	2.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.08e-06	2.67e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—pancreatic cancer	3.04e-06	2.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	2.99e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.88e-06	2.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—pancreatic cancer	2.85e-06	2.47e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.7e-06	2.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	2.68e-06	2.33e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.68e-06	2.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	2.66e-06	2.31e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.63e-06	2.29e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOE—pancreatic cancer	2.56e-06	2.22e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—pancreatic cancer	2.54e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.34e-06	2.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.32e-06	2.01e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.31e-06	2.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.29e-06	1.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.27e-06	1.97e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.23e-06	1.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.03e-06	1.76e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.01e-06	1.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.98e-06	1.72e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.77e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.75e-06	1.52e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.65e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—pancreatic cancer	1.64e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.63e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.53e-06	1.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.4e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.35e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.33e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.14e-06	9.92e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.08e-06	9.37e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—pancreatic cancer	8.8e-07	7.66e-06	CbGpPWpGaD
